Search

Welcome to NRG Oncology!

Welcome to the NRG Oncology Web site! This resource serves to provide current information about NRG Oncology’s exciting research future and the latest updates about plans to support our clinical trial endeavors. We invite you to check back often to learn “what’s new.”

Who We Are

NRG Oncology brings together the unique and complementary research areas of the National Surgical Adjuvant Breast and Bowel Project (NSABP), the Radiation Therapy Oncology Group (RTOG), and the Gynecologic Oncology Group (GOG). NRG Oncology builds upon our more than 150 years of cumulative research  experience to conduct practice defining, multi-institutional clinical trials resulting in the improved survival and quality of life of patients with cancer.

 

NCORP

Learn about the leaders and plans for NRG Oncology's NCORP Research Base.

 

NRG Oncology
Four Penn Center, 1600 JFK Blvd, Suite 1020, Philadelphia, PA 19103
267-519-6630
Contact Us

To receive the NRG Oncology Newsletter and occasional eNews announcements and press releases, please click on the link to complete the requestform. Newsletter Sign Up

 




What’s New

Recently published research results: 

  • A preliminary patient-reported outcomes analysis of high-dose 3D-CRT vs IMRT for intermediate-risk prostate cancer show no differences in outcomes between the two modalities. 
  • The survival benefit of intraperitoneal vs intravenous chemotherapy in women with advanced ovarian cancer extends beyond 10 years.

Read more

The phase II NRG-GY001 trial activates to evaluate the anti-tumor activity of cabozantinib (XL184) in women with persistent or recurrent clear cell ovarian cancer. Read more

NRG-CC002, the first NRG NCORP-sponsored trial, launches to evaluate an assessment tool to gain insight about outcomes in elderly women undergoing treatment for gynecologic cancers  Read more

Merry-Jennifer Markham, MD, a member of the NRG Oncology Social Media Subcommittee, was profiled in the Feb 10 issue of Oncology Times. Read more

Image-guided radiotherapy reduces long-term treatment side effects in patients with soft tissue sarcoma. Read more

In patients with advanced ovarian cancer, the extent of disease at initial diagnosis is a significant prognostic indicator with the level of surgery complexity found not to affect progression-free survival or overall survival. Read more

NSABP B-31 and NCCTG N9831 article named one of top 8 articles downloaded from JCO website in 2014. Read more

Higher-dose radiotherapy results in inferior survival in patients with stage III lung cancer. Read more 

 

 

 

 











Copyright 2015 by NRG Oncology